Načítá se...
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. CD101 has potent in vitro activity and in vivo efficacy against a broad range of Candida and Aspergillus species. The primary objec...
Uloženo v:
| Vydáno v: | Antimicrob Agents Chemother |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Microbiology
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5278714/ https://ncbi.nlm.nih.gov/pubmed/27919901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01627-16 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|